Drug Profile
Research programme: anti-cancer therapeutics - Bionetix/ Southern Research
Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Bionetix; Southern Research Institute
- Class Antineoplastics; Small molecules
- Mechanism of Action Methyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer